Regeneron Pharmaceuticals, Inc. (REGN) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. trimmed its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 112,082 shares of the biopharmaceutical company’s stock after selling 3,119 shares during the quarter. Principal Financial Group Inc. owned approximately 0.11% of Regeneron Pharmaceuticals worth $50,114,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the company. Janus Henderson Group PLC increased its position in shares of Regeneron Pharmaceuticals by 15,495.4% during the second quarter. Janus Henderson Group PLC now owns 1,562,970 shares of the biopharmaceutical company’s stock worth $767,637,000 after purchasing an additional 1,552,948 shares in the last quarter. Jennison Associates LLC increased its position in shares of Regeneron Pharmaceuticals by 74.1% during the second quarter. Jennison Associates LLC now owns 1,292,863 shares of the biopharmaceutical company’s stock worth $634,977,000 after purchasing an additional 550,247 shares in the last quarter. FMR LLC increased its position in shares of Regeneron Pharmaceuticals by 6.3% during the second quarter. FMR LLC now owns 7,039,884 shares of the biopharmaceutical company’s stock worth $3,457,569,000 after purchasing an additional 416,192 shares in the last quarter. Old Mutual Global Investors UK Ltd. increased its position in shares of Regeneron Pharmaceuticals by 500,446.2% during the third quarter. Old Mutual Global Investors UK Ltd. now owns 325,355 shares of the biopharmaceutical company’s stock worth $145,472,000 after purchasing an additional 325,290 shares in the last quarter. Finally, TIAA CREF Investment Management LLC increased its position in shares of Regeneron Pharmaceuticals by 97.8% during the second quarter. TIAA CREF Investment Management LLC now owns 485,336 shares of the biopharmaceutical company’s stock worth $238,368,000 after purchasing an additional 239,937 shares in the last quarter. 67.80% of the stock is owned by institutional investors and hedge funds.

In other news, Chairman P Roy Vagelos sold 15,191 shares of the firm’s stock in a transaction dated Friday, August 18th. The stock was sold at an average price of $470.15, for a total transaction of $7,142,048.65. Following the sale, the chairman now owns 329,543 shares of the company’s stock, valued at approximately $154,934,641.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Robert E. Landry sold 189 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total value of $94,700.34. Following the sale, the chief financial officer now directly owns 10,099 shares in the company, valued at approximately $5,060,204.94. The disclosure for this sale can be found here. Insiders have sold a total of 77,956 shares of company stock worth $36,898,788 in the last three months. Corporate insiders own 10.80% of the company’s stock.

Several brokerages recently commented on REGN. Bank of America Corporation reiterated a “buy” rating and set a $593.00 price target (up from $589.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, July 21st. BMO Capital Markets reiterated a “market perform” rating and set a $484.00 price target (up from $421.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, July 21st. Barclays PLC restated an “equal weight” rating and issued a $450.00 target price (up from $400.00) on shares of Regeneron Pharmaceuticals in a report on Saturday, July 22nd. Canaccord Genuity set a $522.00 target price on Regeneron Pharmaceuticals and gave the company a “buy” rating in a report on Friday, July 28th. Finally, Citigroup Inc. restated a “buy” rating and issued a $575.00 target price on shares of Regeneron Pharmaceuticals in a report on Thursday, September 7th. Two equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. Regeneron Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $481.49.

ILLEGAL ACTIVITY NOTICE: “Regeneron Pharmaceuticals, Inc. (REGN) Shares Sold by Principal Financial Group Inc.” was originally reported by Week Herald and is owned by of Week Herald. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://weekherald.com/2017/11/15/regeneron-pharmaceuticals-inc-regn-shares-sold-by-principal-financial-group-inc.html.

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) opened at $384.80 on Wednesday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.07 and a current ratio of 3.63. Regeneron Pharmaceuticals, Inc. has a 12-month low of $340.09 and a 12-month high of $543.55. The firm has a market capitalization of $42,176.78, a PE ratio of 34.08, a PEG ratio of 1.55 and a beta of 1.56.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share for the quarter, topping the consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The business had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.45 billion. During the same quarter last year, the company earned $3.13 EPS. The business’s quarterly revenue was up 23.0% on a year-over-year basis. research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 13.55 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply